| AD | Atopic dermatitis |
| AZA | Azathioprine |
| BoNT-A | Botulinum toxin A |
| BSA | Body Surface Area |
| COC | Combined oral contraceptives |
| CsA | Cyclosporine |
| DLQI | Dermatology Life Quality |
| EC | European Committee |
| EMA | European Medicines Agencies |
| FDA | Food and Drug Administration |
| GCS | Glucocorticosteroids |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| HLA | Human leukocyte antigen |
| i.m. | Intramuscularis |
| i.v. | Intravenosa |
| IFN | Interferone |
| IL | Interleukin |
| IPL | Intense pulsed light |
| JAK | Januse |
| MMF | Mycophenolate mofetil |
| MTX | Methotrexate |
| PASI | Psoriasis Area and Severity Index |
| RCT | Randomized Clinical Trials |
| sc. | Subcutanea |
| SCORAD | Scoring Atopic Dermatitis |
| SmPC | Summary of Product Characteristics |
| TCI | Topical Calcineurin Inhibitors |
| TNF | Tumor necrosis factor |